BOSTON, Massachusetts — September 8, 2026
Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept in adults with generalized myasthenia gravis (gMG). The milestone keeps the program on track for topline results from the 24-week primary endpoint in the first half of 2027, marking a major step in Vor Bio’s strategy to advance telitacicept toward potential regulatory approvals in the United States, Europe and Japan. UPSTREAM MG is a randomized, double-blind, placebo-controlled Phase 3 study followed by a 48-week open-label extension designed to evaluate longer-term efficacy and safety. The global program builds on clinical experience generated by RemeGen in China, where telitacicept demonstrated statistically significant and clinically meaningful improvements in MG-ADL and QMG scores at Week 24, with continued clinical improvement reported through Week 48 in the open-label extension.
Vor Bio Expands Telitacicept Franchise Into Ocular MG
Vor Bio is also expanding its global telitacicept development program into ocular myasthenia gravis (oMG) through the planned initiation of UPSTREAM oMG, a global Phase 3 registrational trial. First-patient dosing is anticipated in the first half of 2027, extending development of telitacicept beyond generalized disease and toward a broader myasthenia gravis franchise. The expansion builds on the existing clinical development experience with telitacicept in MG, including RemeGen’s ongoing Phase 3 oMG trial in China. Ocular MG primarily affects the muscles controlling the eyes and eyelids and can cause symptoms such as ptosis and diplopia that substantially interfere with daily activities. By pursuing a dedicated registrational program in oMG, Vor Bio is positioning telitacicept for potential future label expansion across the MG disease spectrum while continuing to advance its broader autoimmune development strategy.
Telitacicept Targets BAFF and APRIL Signaling
Telitacicept is a recombinant fusion protein designed to simultaneously inhibit BLyS/BAFF and APRIL, two cytokines involved in the survival of B cells and plasma cells and the production of autoantibodies. Vor Bio is developing the therapy as a differentiated approach to autoimmune disease by targeting upstream drivers of antibody-mediated pathology rather than focusing primarily on downstream reduction of circulating IgG or complete B-cell depletion. The company is advancing telitacicept through global Phase 3 programs in gMG and Sjögren’s disease, while the therapy is already approved in China for multiple autoimmune conditions, including systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, IgA nephropathy and Sjögren’s disease. The expanding clinical program provides Vor Bio with an opportunity to leverage an established clinical and regulatory foundation as it seeks to build a broader international franchise around the dual-target mechanism.
Advertisement
Vor Bio Builds a Broader Global Autoimmune Franchise
Completion of UPSTREAM MG enrollment and expansion into ocular MG strengthen Vor Bio’s strategy to establish telitacicept as a foundational therapy across autoimmune diseases. The company is prioritizing rapid Phase 3 execution while expanding the potential addressable patient population through additional indications. The UPSTREAM MG trial uses change from baseline in MG-ADL score at Week 24 as its primary endpoint, with secondary measures assessing muscle strength, clinical response and patient-reported outcomes. The planned UPSTREAM oMG study represents the next major expansion of the program, with dosing expected to begin in the first half of 2027. Together with the company’s ongoing Sjögren’s disease development program, the trials form the foundation of Vor Bio’s broader global telitacicept franchise. With UPSTREAM MG fully enrolled and a Phase 3 oMG program planned, Vor Bio is moving telitacicept toward multiple potential regulatory opportunities while building a wider autoimmune development and commercialization platfor.
Source: Vor Bio press release
